

Rodd PORTER

16 NOV 2005

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/532,009
				Filing Date	October 22, 2003 (I.A.)
				First Named Inventor	David S. Lawrence
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	4	Attorney Docket Number	96700/996

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
	9	WO 2004/018686 A1	03-04-2004	Cambridge et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.V./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/532,009
				Filing Date	October 22, 2003 (I.A.)
				First Named Inventor	David S. Lawrence
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	2	of	4	Attorney Docket Number	96700/996

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	10	ADAMS, S.R. and TSIEN, R.Y. (1993) "Controlling Cell Chemistry with Caged Compounds." Annu. Rev. Physiol. Vol. 55. pp 755-84.	
	11	ALBANESE, C. et al. (2002) "Recent advances in inducible expression in transgenic mice." Sem. in Cell & Develop. Biol. Vol. 13. pp 129-41.	
	12	ALBANESE, C. et al. (2000) "Sustained mammary gland-directed, ponasterone A-inducible expression in transgenic mice." FASEB J. Vol.14, pp 877-884.	
	13	ANDO, H. et al. (2001) "Photo-mediated gene activation using caged RNA/DNA in zebrafish embryos." Nature Genetics. Vol. 28. pp 317-25.	
	14	ARAKAWA, H. et al. (2001) "Mutant loxP vectors for selectable marker recycle and conditional knock-outs." BMC Biotechnol. Vol. 1, No. 7. pp 1472-79.	
	15	BELSHAW, P.J. et al. (1996) "Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization." Chem. Biol. Vol. 3, No. 9. pp 731-38.	
	16	CHEN, J.D. and EVANS, R.M. (1995) "A transcriptional co-repressor that interacts with nuclear hormone receptors." Nature Vol. 377, pp 454-57.	
	17	CRONIN, C.A. et al. (2001) "The lac operator-repressor system is functional in the mouse." Genes Dev. Vol. 15. pp 1506-17.	
	18	CRUZ, F.G. et al. (2000) "Light-Activated Gene Expression." J. Am. Chem. Soc. Vol. 122. pp 8777-78.	
	19	CURLEY, K. and LAWRENCE, D.S. (1999) "Light-activated proteins." Cur. Opin. Chem. Biol. Vol. 3. pp 84-88.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.V./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/532,009
				Filing Date	October 22, 2003 (I.A.)
				First Named Inventor	David S. Lawrence
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	3	of	4	Attorney Docket Number	96700/996

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	20	DINAN, L. et al. (1999) "An extensiveecdysteroid CoMFA." J. Comput. Aided Mol. Des. Vol. 13. pp 185-207.		
	21	FEIL, R. et al. (1996) "Ligand-activated site-specific recombinaton in mice." Proc. Natl. Acad. Sci. USA. Vol. 93. pp 10887-90.		
	22	FISHER, G.H. et al. (1999) "Development of a flexible and specific gene delivery system for production of murine tumor models." Oncogene. Vol. 18. pp 5253-60.		
	23	FURUTA, T. et al. (1999) "Brominated 7-hydroxycoumarin-4-ylmethyls: Photolabile protecting groups with biologically useful cross-sections for two photon photolysis." Proc. Natl. Acad. Sci. USA. Vol. 96. pp 1193-1200.		
	24	GINGRICH, J.R. and Roder, J. (1998) "Inducible Gene Expression in the Nervous System of Transgenic Mice." Annu. Rev. Neurosci. Vol. 21. pp 377-405.		
	25	MIKITANI, K. (1996) "A New Nonsteroidal Chemical Class of Ligand for the Ecdysteroid Receptor 3, 5-di-tert-butyl-4-hydroxy-N-isobutyl-benzamide Shows Apparent Insect Molting Hormone Activities at Molecular and Cellular Levels." Biochem. Biophys. Res. Comm. Vol. 227. pp 427-32.		
	26	MONROE, W.T. et al. (1999) " Targeting Expression with Light Using Caged DNA." J. Biol. Chem. Vol. 274. No. 30. pp 20895-20900.		
	27	NAGY, A. (2000) "Cre Recombinase: The Universal Reagent for Genome Tailoring." Genesis. Vol. 26, pp 99-109.		
	28	NO, D. et al. (1996) "Ecdysone-inducible gene expression in mammalian cells and transgenic mice." Proc Natl Acad Sci USA. Vol. 93. pp 3346-51.		
	29	ORSULIC, S. et al. (2002) "Induction of ovarian cancer by defined multiple genetic changes in a mouse model system." Cancer Cell. Vol.1. pp 53-62.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.V./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/532,009
				Filing Date	October 22, 2003 (I.A.)
				First Named Inventor	David S. Lawrence
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	4	of	4	Attorney Docket Number	96700/996

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	30	PAO, E. et al. (2003) "Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance." Proc. Natl. Acad. Sci. USA. Vol. 100. No. 15. pp 8764-69.	
	31	PETIT, D.L. et al. (1997) "Chemical Two-Photon Uncaging: a Novel Approach to Mapping Glutamate Receptors." Neuron. Vol. 19. pp 465-71.	
	32	RYDING, A.D.S. et al. (2001) "Conditional transgenic technologies." J. Endocrinol. Vol. 171. pp 1-14.	
	33	SAEZ, E. et al. (2000) "Identification of ligands and coligands for the ecdysone-regulated gene switch." Proc. Natl. Acad. Sci. USA. Vol. 97. No. 26. pp 14512-17.	
	34	SHOCKETT, P.E. and Schatz, D.G. (1996) "Diverse strategies for tetracycline-regulated inducible gene expression." Proc. Natl. Acad. Sci. USA. Vol. 93. pp 5173-76.	
	35	WANG, J. et al. (1998) "ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex." Proc. Natl. Acad. Sci. USA. Vol. 95. pp 10860-65.	

Examiner Signature	/Jake Vu/	Date Considered	10/24/2009
--------------------	-----------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.V./